Sung Woo Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sung Woo Cho has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Moon Kyun Cho
Division of Molecular Cancer Research, Soonchunhyang Medical Research Institute, Soonchunhyang University, Cheonan 31151, Republic of Korea
6 shared publications - Woo Il Kim
Department of Dermatology Soonchunhyang University Hospital Seoul South Korea
5 shared publications Dan Song
Department of Surgery, Soonchunhyang University College of Medicine, Seoul - Korea
4 shared publicationsMoon Soo Lee
Department of Surgery, Soonchunhayng University College of Medicine, Cheonan, Republic of Korea
4 shared publicationsSangchul Yun
4 shared publications- Sangchul Yun
Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea
4 shared publications
Latest Publications
- Open Access
- 30 November 2025
- Published by Korean Innovative Medical Technology Society in Journal of Innovative Medical Technology
- Vol. 3 (2) , 78-81
Acute appendicitis following colonoscopy
Sungwoo Cho, Joo Young Cho, Seong Hwan Kim. J Innov Med Technol 2025;3:78-81. https://doi.org/10.61940/jimt.250006
- 30 November 2025
- Published by Korean Innovative Medical Technology Society in Journal of Innovative Medical Technology
- Vol. 3 (2) , 78-81
Open AccessAcute appendicitis following colonoscopy
Sungwoo Cho, Joo Young Cho, Seong Hwan Kim. J Innov Med Technol 2025;3:78-81. https://doi.org/10.61940/jimt.250006
- 12 March 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (5) , 2533-2541
Endoscopic resection and laparoscopic lymph node dissection for early gastric cancer beyond conventional endoscopic treatment indications: a 10-year outcome study
Background Endoscopic full-thickness gastric resection (EFTGR) with laparoscopic regional lymph node dissection (LLND) and endoscopic submucosal dissection (ESD) with LLND have been investigated as treatment options for early gastric cancer beyond the absolute indications for ESD. However, comparative studies on the long-term outcomes of these procedures are lacking. This study aimed to analyze and compare the 10-year outcomes of both procedures in a real clinical setting. Methods Between January 2009 and December 2013, 28 and 37 patients diagnosed with EGC beyond the absolute indications for ESD were treated with EFTGR with LLND and ESD with LLND, respectively. In both procedures, the dye was injected into the tumor. However, after injection and LLND, EFTGR was performed immediately in the EFTGR with LLND group, whereas LLND was followed by ESD in the ESD with LLND group. The primary endpoint was the 10-year survival rate. Results The EFTGR with LLND group had one case of local recurrence (3.6%) and mortality (3.6%) each, while the ESD with LLND group had none (0.0% for both); however, the differences were not statistically significant (P = 0.247 for each). Furthermore, there was no significant difference in complications such as ischemia and anastomosis leakage between the groups (P = 0.247). Conclusions When the procedures were properly applied, EFTGR with LLND and ESD with LLND did not increase the 10-year mortality in patients with EGC beyond the absolute ESD indications compared with conventional radical gastrectomy.
- 12 March 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (5) , 2533-2541
Endoscopic resection and laparoscopic lymph node dissection for early gastric cancer beyond conventional endoscopic treatment indications: a 10-year outcome study
Background Endoscopic full-thickness gastric resection (EFTGR) with laparoscopic regional lymph node dissection (LLND) and endoscopic submucosal dissection (ESD) with LLND have been investigated as treatment options for early gastric cancer beyond the absolute indications for ESD. However, comparative studies on the long-term outcomes of these procedures are lacking. This study aimed to analyze and compare the 10-year outcomes of both procedures in a real clinical setting. Methods Between January 2009 and December 2013, 28 and 37 patients diagnosed with EGC beyond the absolute indications for ESD were treated with EFTGR with LLND and ESD with LLND, respectively. In both procedures, the dye was injected into the tumor. However, after injection and LLND, EFTGR was performed immediately in the EFTGR with LLND group, whereas LLND was followed by ESD in the ESD with LLND group. The primary endpoint was the 10-year survival rate. Results The EFTGR with LLND group had one case of local recurrence (3.6%) and mortality (3.6%) each, while the ESD with LLND group had none (0.0% for both); however, the differences were not statistically significant (P = 0.247 for each). Furthermore, there was no significant difference in complications such as ischemia and anastomosis leakage between the groups (P = 0.247). Conclusions When the procedures were properly applied, EFTGR with LLND and ESD with LLND did not increase the 10-year mortality in patients with EGC beyond the absolute ESD indications compared with conventional radical gastrectomy.
- 21 September 2020
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 313 (7) , 583-591
Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell survival and migration
Cutaneous melanoma is known to be one of the most dangerous skin cancers because of its metastatic functions. Today, it is essential to investigate specific biomarkers for the target treatment in many diseases including cancers. DJ-1 protein, also known as Parkinson disease 7, has various functions associated with cancer progression including cell survival and migration. Phosphatase and tensin homolog (PTEN) is a tumor suppressor that regulates the PI3K/AKT signaling pathway and its mutations have been reported to frequently occur in many cancers such as thyroid, breast and skin. Recently, DJ-1 has been identified as a negative regulator of PTEN in many human cancer cells. However, the impacts and relationship of DJ-1 and PTEN have not been studied yet in melanoma. To confirm the expression of DJ-1 and PTEN in melanoma compared to normal skin tissues and find out functions of DJ-1 in melanoma cells, Western blot analysis and immunohistochemical staining were used. Transfection of G361 cells with DJ-1-specific small interfering RNA was performed to figure out the roles of DJ-1 and the relationship between DJ-1 and PTEN in melanoma cells. In our study, the DJ-1 protein was significantly increased with loss of PTEN protein in melanoma compared to that in normal skin. Inhibition of DJ-1 in G361 cells induced apoptosis, and suppressed cell survival and migration. Furthermore, suppression of DJ-1 in G361 cells increased the expression of cleaved caspase-3, cleaved PARP, Bax, p53, and Daxx as well as PTEN, while it decreased expression of survivin, caspase-3, and PARP. Also, downregulated DJ-1 inhibited phosphorylation of AKT in G361 cells. Collectively, DJ-1 overexpression could affect the proliferative and invasive capabilities of melanoma cells via regulating the PTEN/AKT pathway and apoptosis-related proteins. This study suggests that DJ-1 may be a potential target for the treatment of melanoma.
- 21 September 2020
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 313 (7) , 583-591
Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell survival and migration
Cutaneous melanoma is known to be one of the most dangerous skin cancers because of its metastatic functions. Today, it is essential to investigate specific biomarkers for the target treatment in many diseases including cancers. DJ-1 protein, also known as Parkinson disease 7, has various functions associated with cancer progression including cell survival and migration. Phosphatase and tensin homolog (PTEN) is a tumor suppressor that regulates the PI3K/AKT signaling pathway and its mutations have been reported to frequently occur in many cancers such as thyroid, breast and skin. Recently, DJ-1 has been identified as a negative regulator of PTEN in many human cancer cells. However, the impacts and relationship of DJ-1 and PTEN have not been studied yet in melanoma. To confirm the expression of DJ-1 and PTEN in melanoma compared to normal skin tissues and find out functions of DJ-1 in melanoma cells, Western blot analysis and immunohistochemical staining were used. Transfection of G361 cells with DJ-1-specific small interfering RNA was performed to figure out the roles of DJ-1 and the relationship between DJ-1 and PTEN in melanoma cells. In our study, the DJ-1 protein was significantly increased with loss of PTEN protein in melanoma compared to that in normal skin. Inhibition of DJ-1 in G361 cells induced apoptosis, and suppressed cell survival and migration. Furthermore, suppression of DJ-1 in G361 cells increased the expression of cleaved caspase-3, cleaved PARP, Bax, p53, and Daxx as well as PTEN, while it decreased expression of survivin, caspase-3, and PARP. Also, downregulated DJ-1 inhibited phosphorylation of AKT in G361 cells. Collectively, DJ-1 overexpression could affect the proliferative and invasive capabilities of melanoma cells via regulating the PTEN/AKT pathway and apoptosis-related proteins. This study suggests that DJ-1 may be a potential target for the treatment of melanoma.
- Open Access
- 1 September 2020
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 36 (3) , 174-179
Acute Traumatic Arterial Occlusions Combined with Massive Morel-Lavallee Lesions Treated by Percutaneous Angioplasty, Multiple Debridements and Skin Grafts
Morel-Lavallee lesions (MLL) create pre-fascial space by shearing the subcutaneous tissues away from the underlying fascia, in a patient with trauma. Necrosis of the overlying skin can develop over a wide area of the lesion. The lesion might be contaminated by the surgical site due to careless intrusion when treating the combined arteriopathy. A 70-year-old woman presented with avulsion of the skin over the right foot and bilateral leg pain following a car accident. Computed tomography showed bilateral popliteal artery occlusion with large hematoma on both legs. Percutaneous angioplasty was performed with successful restoration of the flow. However, the skin color changes over time. Necrosis of the skin occurred over a wide area of the right leg. Extensive debridement was performed, and the defect was covered with a skin graft. MLLs can occur in patients with multiple traumas, multiple vascular injuries, and complex skeletal injury. Vascular surgeons treating multiple traumas should be aware of the diagnostic and management options for MLL. It should be diagnosed early because it can be difficult to manage once the overlying skin develops necrosis.
- 1 September 2020
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 36 (3) , 174-179
Open AccessAcute Traumatic Arterial Occlusions Combined with Massive Morel-Lavallee Lesions Treated by Percutaneous Angioplasty, Multiple Debridements and Skin Grafts
Morel-Lavallee lesions (MLL) create pre-fascial space by shearing the subcutaneous tissues away from the underlying fascia, in a patient with trauma. Necrosis of the overlying skin can develop over a wide area of the lesion. The lesion might be contaminated by the surgical site due to careless intrusion when treating the combined arteriopathy. A 70-year-old woman presented with avulsion of the skin over the right foot and bilateral leg pain following a car accident. Computed tomography showed bilateral popliteal artery occlusion with large hematoma on both legs. Percutaneous angioplasty was performed with successful restoration of the flow. However, the skin color changes over time. Necrosis of the skin occurred over a wide area of the right leg. Extensive debridement was performed, and the defect was covered with a skin graft. MLLs can occur in patients with multiple traumas, multiple vascular injuries, and complex skeletal injury. Vascular surgeons treating multiple traumas should be aware of the diagnostic and management options for MLL. It should be diagnosed early because it can be difficult to manage once the overlying skin develops necrosis.
- 3 April 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3357-3366
The efficacy of bleomycin for treating keloid and hypertrophic scar: A systematic review and meta‐analysis
Background: Pathologic scars can lead to itching, erythema, and psychological stress due to cosmetic problems. Bleomycin, one of anticancer agents, has been used for treating keloid or hypertrophic scar. Some studies have shown that bleomycin can induce markedly scar improvement.Aims: To evaluate the efficacy of bleomycin compared to corticosteroid as well as other treatments for keloid or hypertrophic scar using meta‐analysis methods.Methods: A computerized search was performed in different databases including Cochrane, Embase, and PubMed. Three randomized controlled trials (RCTs) and two controlled clinical trials (CCTs) were included. Then, statistical analyses of extracted outcome data from the studies were calculated using Rex (version 3.0.1; RexSoft Inc).Results: Scar improvement was significantly increased in the bleomycin group compared to the triamcinolone acetonide (TAC) group (SMD: 0.59, 95% CI: 0.30‐0.88, P < .0001). In addition, there was also statistically significant difference between the bleomycin group and the 5‐FU group (SMD: 1.37, 95% CI: 0.88‐1.85, P < .0001). Bleomycin increased relatively scar improvement compared to TAC combined with 5‐FU, although there was no statistical difference (SMD: 0.63, 95% CI: −0.59‐1.84, P = .3108). Furthermore, bleomycin demonstrated significantly increased improvement of scar compared to TAC combined with cryotherapy (SMD: 1.11, 95% CI: 0.48‐1.74, P = .0006).Conclusions: This meta‐analysis found that bleomycin was more effective for treating keloid or hypertrophic scar than other treatments including TAC, 5‐FU, TAC combined with 5‐FU, and TAC combined with cryotherapy. However, further comprehensive studies, including randomized controlled trials, are needed to perform objective analysis.
- 3 April 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3357-3366
The efficacy of bleomycin for treating keloid and hypertrophic scar: A systematic review and meta‐analysis
Background: Pathologic scars can lead to itching, erythema, and psychological stress due to cosmetic problems. Bleomycin, one of anticancer agents, has been used for treating keloid or hypertrophic scar. Some studies have shown that bleomycin can induce markedly scar improvement.Aims: To evaluate the efficacy of bleomycin compared to corticosteroid as well as other treatments for keloid or hypertrophic scar using meta‐analysis methods.Methods: A computerized search was performed in different databases including Cochrane, Embase, and PubMed. Three randomized controlled trials (RCTs) and two controlled clinical trials (CCTs) were included. Then, statistical analyses of extracted outcome data from the studies were calculated using Rex (version 3.0.1; RexSoft Inc).Results: Scar improvement was significantly increased in the bleomycin group compared to the triamcinolone acetonide (TAC) group (SMD: 0.59, 95% CI: 0.30‐0.88, P < .0001). In addition, there was also statistically significant difference between the bleomycin group and the 5‐FU group (SMD: 1.37, 95% CI: 0.88‐1.85, P < .0001). Bleomycin increased relatively scar improvement compared to TAC combined with 5‐FU, although there was no statistical difference (SMD: 0.63, 95% CI: −0.59‐1.84, P = .3108). Furthermore, bleomycin demonstrated significantly increased improvement of scar compared to TAC combined with cryotherapy (SMD: 1.11, 95% CI: 0.48‐1.74, P = .0006).Conclusions: This meta‐analysis found that bleomycin was more effective for treating keloid or hypertrophic scar than other treatments including TAC, 5‐FU, TAC combined with 5‐FU, and TAC combined with cryotherapy. However, further comprehensive studies, including randomized controlled trials, are needed to perform objective analysis.
- Open Access
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 98 (4) , 159-167
Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways
Lee YJ, et al. Ann Surg Treat Res. 2020 Apr;98(4):159-167. https://doi.org/10.4174/astr.2020.98.4.159
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 98 (4) , 159-167
Open AccessOverexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways
Lee YJ, et al. Ann Surg Treat Res. 2020 Apr;98(4):159-167. https://doi.org/10.4174/astr.2020.98.4.159
- Open Access
- 31 October 2019
- Published by The Society of Korean Medicine Rehabilitation in Journal of Korean Medicine Rehabilitation
- Vol. 29 (4) , 135-142
A Case of Combined Korean Medicine Treatment for Recurrent Limb Weakness after Guillain-Barré Syndrome Improvement: Case Report
Song-Mi Park, K.M.D., Sung-Woo Cho, K.M.D.. J Korean Med Rehabi 2019;29:135-42. https://doi.org/10.18325/jkmr.2019.29.4.135
- 31 October 2019
- Published by The Society of Korean Medicine Rehabilitation in Journal of Korean Medicine Rehabilitation
- Vol. 29 (4) , 135-142
Open AccessA Case of Combined Korean Medicine Treatment for Recurrent Limb Weakness after Guillain-Barré Syndrome Improvement: Case Report
Song-Mi Park, K.M.D., Sung-Woo Cho, K.M.D.. J Korean Med Rehabi 2019;29:135-42. https://doi.org/10.18325/jkmr.2019.29.4.135
- 2 May 2019
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 42 (6) , 531-542
Flavonoid morin inhibits proliferation and induces apoptosis of melanoma cells by regulating reactive oxygen species, Sp1 and Mcl-1
Reactive oxygen species (ROS) is associated with cancer progression in different cancers, including melanoma. It also affects specificity protein (Sp1), a transcription factor. Flavonoid morin is known to inhibit growth of cancer cells, including lung cancer and breast cancer. Herein, we hypothesized that morin can inhibit cancer activities in melanoma by altering ROS generation. The aim of this study is to determine the effects of morin and its underlying mechanisms in melanoma cells. Effects of morin on cell proliferation and apoptosis were determined using standardized assays. Changes in pro-apoptotic and anti-apoptotic proteins were analyzed by western blot analysis. Cellular ROS levels and mitochondrial function were evaluated by measuring DCF-DA fluorescence and rhodamine-123 fluorescence intensities, respectively. Morin induced ROS production and apoptosis, as presented by increased proportion of cells with Annexin V-PE(+) staining and sub-G0/G1 peak in cell cycle analysis. It also downregulated Sp1, Mcl-1, Bcl-2, and caspase-3 but upregulated cleaved caspase-3, Bax, and PUMA. In immunohistochemical staining, Sp1 was overexpressed in melanoma tissues compared to normal skin tissues. Collectively, our data suggest that morin can induce apoptosis of melanoma cells by regulating pro-apoptotic and anti-apoptotic proteins through ROS, and may be a potential substance for treatment of melanoma.
- 2 May 2019
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 42 (6) , 531-542
Flavonoid morin inhibits proliferation and induces apoptosis of melanoma cells by regulating reactive oxygen species, Sp1 and Mcl-1
Reactive oxygen species (ROS) is associated with cancer progression in different cancers, including melanoma. It also affects specificity protein (Sp1), a transcription factor. Flavonoid morin is known to inhibit growth of cancer cells, including lung cancer and breast cancer. Herein, we hypothesized that morin can inhibit cancer activities in melanoma by altering ROS generation. The aim of this study is to determine the effects of morin and its underlying mechanisms in melanoma cells. Effects of morin on cell proliferation and apoptosis were determined using standardized assays. Changes in pro-apoptotic and anti-apoptotic proteins were analyzed by western blot analysis. Cellular ROS levels and mitochondrial function were evaluated by measuring DCF-DA fluorescence and rhodamine-123 fluorescence intensities, respectively. Morin induced ROS production and apoptosis, as presented by increased proportion of cells with Annexin V-PE(+) staining and sub-G0/G1 peak in cell cycle analysis. It also downregulated Sp1, Mcl-1, Bcl-2, and caspase-3 but upregulated cleaved caspase-3, Bax, and PUMA. In immunohistochemical staining, Sp1 was overexpressed in melanoma tissues compared to normal skin tissues. Collectively, our data suggest that morin can induce apoptosis of melanoma cells by regulating pro-apoptotic and anti-apoptotic proteins through ROS, and may be a potential substance for treatment of melanoma.
- 12 March 2019
- Published by Springer Nature in Journal of Mechanical Science and Technology
- Vol. 33 (3) , 1293-1303
Development of a 3D breast shape generation and deformation system for breast implant fabrication
- 12 March 2019
- Published by Springer Nature in Journal of Mechanical Science and Technology
- Vol. 33 (3) , 1293-1303
Development of a 3D breast shape generation and deformation system for breast implant fabrication
- Open Access
- 26 January 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 11 (1) , 45-55
Regenerative potential of mouse embryonic stem cell-derived PDGFRα+ cardiac lineage committed cells in infarcted myocardium
- 26 January 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 11 (1) , 45-55
Open AccessRegenerative potential of mouse embryonic stem cell-derived PDGFRα+ cardiac lineage committed cells in infarcted myocardium